Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus Bevacizumab vs Chemotherapy plus Bevacizumab in Advanced Non-Squamous NSCLC
NCT00536640Phase 2Completed
- Sponsor
- Aktion Bronchialkarzinom
- Start
- Nov 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Aktion Bronchialkarzinom. Started Nov 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00536640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536640.